Liquidia's LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension

Stock Information for Liquidia Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.